United Therapeutics CORP Form 4 insider transactions

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock through a trust, according to a recent SEC Form 4 filing.

Director Richard Giltner exercised stock options and sold shares of United Therapeutics Corp on November 5, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Christopher Causey of United Therapeutics Corporation sold 510 shares of common stock on November 1, 2024, at a price of $376.6281 per share.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold a portion of the acquired shares on November 1, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on October 21, 2024, according to a Form 4 filing with the SEC.

Paul Mahon, EVP & General Counsel of United Therapeutics, executed share tracking award exercises on October 3 and October 17, 2024, according to a Form 4 filing.

James Edgemond, CFO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO of United Therapeutics, exercised stock options and sold shares of common stock on September 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO of United Therapeutics, exercised stock options and sold shares of common stock on September 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards for 7,700 shares under a pre-arranged 10b5-1 plan.

Director Judy D. Olian reports the acquisition and disposition of United Therapeutics Corp (UTHR) common stock and stock options on September 17, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond, CFO of United Therapeutics, exercised stock options and sold shares of common stock on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Christopher Patusky of United Therapeutics Corp. executed stock option exercises and sales on September 3rd and 4th, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock options and sold shares of common stock on August 26, 2024, under a pre-arranged 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on August 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 22 and 23, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan on August 20 and 21, 2024.

Director Christopher Causey reported the acquisition and disposal of United Therapeutics Corp [UTHR] common stock on August 21, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock options and sold shares on August 19, 2024, under a pre-arranged 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on August 19, 2024, according to a Form 4 filing with the SEC.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 15 and 16, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 13 and 14, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 9 and August 12, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan on August 7th and 8th, 2024.

Michael Benkowitz, President and COO of United Therapeutics, executed stock option exercises and sales on August 7, 2024, involving both direct and indirect ownership through trusts.